S
Sharon Fong
Researcher at Genentech
Publications - 8
Citations - 3182
Sharon Fong is an academic researcher from Genentech. The author has contributed to research in topics: Tumor necrosis factor alpha & Apoptosis. The author has an hindex of 8, co-authored 8 publications receiving 3109 citations.
Papers
More filters
Journal ArticleDOI
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi,Roger Pai,Sharon Fong,Susan Leung,David A. Lawrence,Scot A. Marsters,Christine Blackie,Ling Chang,Amy E. McMurtrey,Andrea Hebert,Laura DeForge,Iphigenia Koumenis,Derf Lewis,Louise A. Harris,Jeanine L. Bussiere,Hartmut Koeppen,Zahra Shahrokh,Ralph H. Schwall +17 more
TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
Heidi LeBlanc,David A. Lawrence,Eugene Varfolomeev,Klara Totpal,John Morlan,Peter Schow,Sharon Fong,Ralph H. Schwall,Dominick Sinicropi,Avi Ashkenazi +9 more
TL;DR: It is shown that Bax mutation in mismatch repair–deficient tumors can cause resistance to death receptor–targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.
Journal ArticleDOI
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Hongkui Jin,Renhui Yang,Sharon Fong,Klara Totpal,David S. Lawrence,Zhong Zheng,Jed Ross,Hartmut Koeppen,Ralph H. Schwall,Avi Ashkenazi +9 more
TL;DR: Evidence is provided for in vivo activity of Apo2L/TRAIL against lung tumor xenografts and the potential of this ligand for advancing current lung cancer treatment strategies is underscored.
Journal Article
Overexpression of the Retinoic Acid-responsive Gene Stra6 in Human Cancers and Its Synergistic Induction by Wnt-1 and Retinoic Acid
Wayne Szeto,Wen Jiang,David Tice,Bonnee Rubinfeld,P Hollingshead,Sharon Fong,Debra L. Dugger,Thinh Pham,Daniel G. Yansura,Terence A. Wong,J. Christopher Grimaldi,Racquel Corpuz,Jennifer S. Singh,Gretchen Frantz,Brigitte Devaux,Craig W. Crowley,Ralph H. Schwall,David A. Eberhard,Luca Rastelli,Paul Polakis,Diane Pennica +20 more
TL;DR: The data support a model in which Wnt-1 signaling synergizes with retinoids to activate retinoic acid receptor-gamma-responsive genes in human cancers, and treatment of human colorectal cancer cell lines with retinoIC acid resulted in the up-regulation of Stra6 mRNA and accumulation of Stra 6 protein at the cell membrane.
Journal ArticleDOI
Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling.
David Tice,Wayne Szeto,Irina Soloviev,Bonnee Rubinfeld,Sharon Fong,Debra L. Dugger,Jane Winer,P. Mickey Williams,David Wieand,Victoria Smith,Ralph H. Schwall,Diane Pennica,Paul Polakis +12 more
TL;DR: Great attention was given to genes encoding cell surface antigens that were selectively up-regulated by the combination of Wnt-1 and retinoic acid, including the tumor necrosis factor family 4-1BB ligand, ephrin B1,stra6, autotaxin, and ISLR.